Download Files:
SAR502250
$580 – $5,000
Products Details
Product Description
– SAR502250 is a potent, selective, ATP competitive, orally active and brain-penetrant inhibitor of GSK3, with an IC50 of 12 nM for human GSK-3β. SAR502250 displays antidepressant-like activity. SAR502250 can be used for the research of Alzheimer’s disease (AD)[1][2].
Web ID
– HY-137472
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Neuroscience-Neurodegeneration
Molecular Formula
– C19H18FN5O2
References
– [1]Fukunaga K, et, al. 2-(2-Phenylmorpholin-4-yl)pyrimidin-4(3H)-ones; a new class of potent, selective and orally active glycogen synthase kinase-3β inhibitors. Bioorg Med Chem Lett. 2013 Dec 15;23(24):6933-7.|[2]Griebel G, et, al. The selective GSK3 inhibitor, SAR502250, displays neuroprotective activity and attenuates behavioral impairments in models of neuropsychiatric symptoms of Alzheimer’s disease in rodents. Sci Rep. 2019 Dec 2;9(1):18045.
CAS Number
– 503860-57-9
Molecular Weight
– 367.38
Compound Purity
– 99.63
SMILES
– O=C1C=C(C2=NC=NC=C2)N=C(N3C[C@H](C4=CC=C(F)C=C4)OCC3)N1C
Clinical Information
– No Development Reported
Research Area
– Neurological Disease
Solubility
– DMSO : 100 mg/mL (ultrasonic)
Target
– GSK-3
Isoform
– GSK-3β
Pathway
– PI3K/Akt/mTOR;Stem Cell/Wnt
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
